Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monte Rosa Therapeutics

6.06
+0.21003.59%
Post-market: 6.060.00000.00%16:13 EST
Volume:831.79K
Turnover:4.98M
Market Cap:372.30M
PE:-3.43
High:6.14
Open:5.79
Low:5.73
Close:5.85
Loading ...

Company Profile

Company Name:
Monte Rosa Therapeutics
Exchange:
NASDAQ
Establishment Date:
2019
Employees:
133
Office Location:
321 Harrison Avenue,Suite 900,Boston,Massachusetts,United States
Zip Code:
02118
Fax:
- -
Introduction:
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
Markus Warmuth
Chief Executive Officer, President and Director
Alexander Mayweg
Director and Non-Executive Chair of the Board
Ali Behbahani
Director
Andrew Schiff
Director
Bradley J. Bolzon
Director
Chandra P. Leo
Director
Christine Siu
Director
Kimberly Blackwell
Director

Shareholders

Name
Position
Markus Warmuth
Chief Executive Officer, President and Director
Ajim Tamboli
Chief Financial Officer
Filip Janku
Chief Medical Officer
John Castle
Chief Data Scientist
Owen B. Wallace
Chief Scientific Officer
Sharon Townson
Chief Technology Officer